Tag
Complement deposition on platelets identifies a biologically distinct subset of adult ITP associated with higher platelet turnover and more first-line treatment refractoriness.
A novel statistical model predicts chronic immune thrombocytopenia (ITP) in children at diagnosis, using age, sex, immunoglobulin levels, and lab values, offering early clinical guidance.
This Phase 2 basket trial highlights the divergent efficacy of the oral factor B inhibitor iptacopan, showing significant hemoglobin improvements in Cold Agglutinin Disease but failing to meet platelet response endpoints in Immune Thrombocy
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
